Protective effects of dexmedetomidine on the ischemic myocardium in patients undergoing rheumatic heart valve replacement surgery
One such investigation, known as the SUSTAIN-6 trial, was a moderate-sized trial that examined use of the once-weekly injectable agent semaglutide on cardiovascular outcomes when compared with placebo
We cant apply the findings to humans due to different metabolism and physiology
In some cases, switching to a different medication with a different pharmacokinetic profile may improve tolerability
Second, proline substitutions at positions 25, 28, and 29 reduce the tendency to form beta-sheet structures that lead to aggregation
Avakh A, Grant GD, Cheesman MJ, Kalkundri T, Hall S